Lipids and Cardiovascular Pathology

You are here

Home » Research Groups » Lipids and Cardiovascular Pathology
Responsible: 

Concepción Vicenta Llorente Cortés

Research Scientist
Department: 
Experimental Pathology

Research Lines: 

Molecular mechanisms involved in the modulation of LRP1 by cardiovascular risk factors.

Impact of LRP1 on vascular and myocardial cholesterol accumulation.

Impact of lipoproteins on LRP1-Intracellular signal pathways under normoxic and hypoxic conditions.

Alterations in LRP1 expression and LRP1-intracellular signal pathways in hypoxia/ischaemia in in vitro and in vivo models.

Lipids and diabetic cardiomyopathy.

Lipids and breast cancer.

LRP1 and inflammation.

Circulating non-coding RNAs as biomarkers of cardiovascular disease.

Role of non-coding RNAs in vascular lipid accumulation.

Role of non-coding RNAs in myocardial lipid accumulation.

 

Scientific challenges:

Integrate genomic and functional in vivo studies to validate LRP1 as a new therapeutical target and potential biomarker in cardiometabolic diseases

Identify and validate circulating non-coding RNAs as potential biomarkers in cardiovascular diseases

Maintain and amplify relationship with IIB Sant Pau groups regarding translation in cardiometabolism.

Maintain and strengthen national and international collaborations to set up future applications for European funding.

Establish collaborations with companies with the aim of developing new products useful for prognosis, diagnosis and treatment of

cardiometabolic diseases.

 

Current projects:

  • Name of the project: FUNDACIÓN BBVA 2019 AYUDAS A EQUIPOS DE INVESTIGACIÓN CIENTÍFICA. IMAGEN MOLECULAR.Translational Molecular Imaging for Detection of  Cholesterol. Entrapment in the Vasculature with 68Ga-labeled LRP1-derived Peptides. Centros participantes: CSIC, IR-SantPau, Hospital Vall d'Hebró, CIEMAT.  Duration: 3 years. Total amount: 125000 euros
  • Concesión MINECO para formar la RED DE INVESTIGACIÓN "Enfermedades Metabóloicas y Cáncer". RED2018-102799-T (REDEMyC). Coordinador: José Carlos Fernández-Checa. 30.000€. Grupos participantes: Carles Enrich (UB), Carmen García Ruiz (CSIC), Carmen Berasain Lasarte (CIMA), Vicenta Llorente Cortés (CSIC, IIB-SantPau), Pilar Navarro Medrano (CSIC, IMIM), Manuel Romero Gómez (IBS, Universidad de Sevilla), Carmelo García Monzón (Hospital Universitario Santa Cristina, Instituto Investigación Sanitaria Princesa), Josep Julvé Gil (IR-SantPau). Duración: 2019-2021.
  • Name of the project: LRP1 as a source of therapeutic, diagnostic and prognostic tools in cardiovascular disease. Reference: 201521_10 .Entity where project took place: IIBB-CSIC, IIB Sant Pau, Hospital Sta. Creu i St. Pau. City of entity: Barcelona, Catalonia, Spain. Name principal investigator (PI, Co-PI....): Vicenta Llorente Cortés. Funding entity or bodies: Fundació Marató TV3 (201521_10). Start-End date: 01/09/2016 - 01/09/2019. Duration: 3 years. Total amount: 199.511,25 €.
  • Name of the project: Development of an innovative therapy for the treatment of atherosclerosis through the inhibition of the vascular accumulation of cholesterol. Reference: RTC-2016-5078-1. Coordinating company: Iproteos. Entity where project took place: Cardiovascular Research Center (CSIC-ICCC), IIB Sant Pau, Hospital Sta. Creu i St. Pau. City of entity: Barcelona, Catalonia, Spain. Name principal investigator (PI, Co-PI....): Vicenta Llorente Cortés. Funding entity or bodies: Ministry of Economy, Industry and Competitiveness (RETOS-COLABORACION: RTC-2016-5078-1). Start-End date: 01/01/2017 - 01/01/2019. Duration: 3 years. Total amount: 787.372,4 €.
  • Name of the project: The link between myocardial LRP1 and circulating levels of natriuretic peptide ANP as a source of new diagnostic and therapeutic options in type 2 diabetes. Reference: PI18/01584. Entity where project took place: IIBB-CSIC, IIB Sant Pau, Hospital Sta. Creu i St. Pau. City of entity: Barcelona, Catalonia, Spain. Name principal investigator (PI, Co-PI....): Vicenta Llorente Cortés. Funding entity or bodies: Instituto de Salud Carlos III. Start-End date: 01/01/2019 - 01/09/2022. Duration: 3 years. Total amount: 168.795 €.